PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29599346
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After 
      Complete Cytoreductive Surgery.
PG  - 2247-2252
AB  - BACKGROUND/AIM: We aimed to evaluate the impact of bevacizumab on the lymphocele 
      rate in patients after complete cytoreductive surgery for advanced ovarian
      cancer. PATIENTS AND METHODS: This retrospective study included patients with
      advanced ovarian cancer who had undergone complete cytoreductive surgery with
      pelvic and para-aortic lymphadenectomy at the Gustave Roussy Institute from 2005 
      to 2014. The introduction of bevacizumab was discussed in a multidisciplinary
      meeting. RESULTS: During the study period, 247 patients were included; 24.6% of
      patients (61 patients) received adjuvant bevacizumab. The rate of symptomatic
      lymphocele was 34% (84 patients). In the lymphocele group, patients tended to
      receive adjuvant bevacizumab more often than did the control group (32% and 21%, 
      respectively, p=0.05). In multivariate analysis, bevacizumab was not
      significantly associated with the risk of symptomatic lymphocele (hazard
      ratio(HR)=1.62, 95% confidence interval(CI)=0.87-3.01, p=0.12). CONCLUSION:
      Adjuvant bevacizumab has no impact on the formation or duration of symptomatic
      lymphocele in patients after complete cytoreductive surgery for advanced ovarian 
      cancer.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Perrin, Morgane
AU  - Perrin M
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France.
FAU - Bentivegna, Enrica
AU  - Bentivegna E
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France.
FAU - Bonneau, Claire
AU  - Bonneau C
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France.
FAU - Uzan, Catherine
AU  - Uzan C
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France.
FAU - Leary, Alexandra
AU  - Leary A
AD  - Department of Oncology, Gustave Roussy Institute, Villejuif, France.
FAU - Pautier, Patricia
AU  - Pautier P
AD  - Department of Oncology, Gustave Roussy Institute, Villejuif, France.
FAU - Genestie, Catherine
AU  - Genestie C
AD  - Department of Pathology, Gustave Roussy Institute, Villejuif, France.
FAU - Morice, Philippe
AU  - Morice P
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France.
FAU - Gouy, Sebastien
AU  - Gouy S
AD  - Department of Surgery, Gustave Roussy Institute, Villejuif, France
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bevacizumab/*therapeutic use
MH  - Combined Modality Therapy
MH  - Cystadenocarcinoma, Serous/drug therapy/epidemiology/pathology/surgery
MH  - Cytoreduction Surgical Procedures
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lymphocele/*epidemiology
MH  - Middle Aged
MH  - Ovarian Neoplasms/*drug therapy/*epidemiology/pathology/*surgery
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - *Lymphocele
OT  - *bevacizumab
OT  - *lymphadenectomy
OT  - *ovarian cancer
OT  - *surgery
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2017/10/31 00:00 [received]
PHST- 2018/02/02 00:00 [revised]
PHST- 2018/02/05 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2247 [pii]
AID - 10.21873/anticanres.12468 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2247-2252. doi: 10.21873/anticanres.12468.